Aureka Biotechnologies closed a $100 million Series B to advance biological foundation models, AI agents and closed-loop experimental drug discovery infrastructure.
- Amount
- $100M
- Stage
- Series B
- Announced
- 11 August 2026
- Investors
- Granite Asia, HighLight Capital, MPCi, NRL Capital
- Use of funds
- Research and large-scale training of next-generation biological foundation models, and upgrading Lab-in-the-Loop
- Total raised
- $200M to date
- Checked
- Announced by the company